drugset

drugset / Trial / NCT00591734

RAD001 Plus Bevacizumab in Metastatic Melanoma

NCT00591734 ↗

Phase 2 Completed 57 enrolled SCRI Development Innovations, LLC Genentech, Inc. · collab Novartis · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a non-randomized, open label Phase II study comparing bevacizumab and everolimus in the treatment of metastatic melanoma.

Timeline

Start: 2008-01
Primary completion: 2010-10
Completion: 2011-10

Publications

Results Hainsworth JD, Infante JR, Spigel DR, Peyton JD, Thompson DS, Lane CM, Clark BL, Rubin MS, Trent DF, Burris HA 3rd. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer. 2010 Sep 1;116(17):4122-9. doi: 10.1002/cncr.25320.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	—
Subject	Everolimus	Small molecule	10 mg	Oral

Indications